Bausch + Lomb Corporation

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 17, 2025, Bausch + Lomb Corporation (the “Company”) announced the appointment of Eduardo C. Alfonso, MD and Steven H. Collis to its board of directors (the “Board”), effective January 1, 2026, to fill the vacancies created by the departure of Brett Icahn and Gary Hu from the Board in August 2025. The Board has determined that each of Dr. Alfonso and Mr. Collis is independent in accordance with applicable New York Stock Exchange and Toronto Stock Exchange rules and the Company’s corporate governance guidelines. Dr. Alfonso and Mr. Collis have not been appointed to serve on any committees of the Board. Dr. Alfonso and Mr. Collis will receive compensation in accordance with the Company’s Non-Employee Directors Compensation Policy (as in effect from time to time) and have entered into the Company’s standard form of director indemnification agreement. There are no arrangements or understandings between any of Dr. Alfonso and Mr. Collis and any other person pursuant to which any of Dr. Alfonso and Mr. Collis was selected as a director, and there are no transactions in which the Company is a party and in which any of Dr. Alfonso and Mr. Collis has a material interest subject to disclosure under Item 404(a) of Regulation S-K. A copy of the press release announcing the appointments is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.